Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Unknown status
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
To study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of
non-small cell lung cancer, patients will be randomly assigned to the group one (endostar
combined with docetaxel and cisplatin) and group two (docetaxel and cisplatin).
- The serum concentrations of Endostatin,VEGF and bFGF are determined.
- Blood circulating endothelial cells (CECs) and circulating hematopoietic progenitor
cells (CPCs) will be measured by flow cytometer.
- Statistical analysis will be applied to study the relationship between the levels of
Endostatin, VEGF, bFGF, CECs and CPCs and the clinical outcomes such as objective
response rate(ORT), time to progression (TTP), mean survival time(MST), toxicity and
quality of life (QOL).